Introduction

In a groundbreaking development, UNICEF has signed an agreement that locks in the MVA-BN mpox vaccine at the lowest market price for 77 low- and lower-middle-income countries. This crucial step, announced on September 26, 2024, is designed to ensure vaccine accessibility amidst the rising mpox crisis, while also establishing a framework for sustained vaccine supply into 2025.

Details of the Agreement

The agreement stems from an emergency tender launched on August 29, just weeks after mpox was declared a public health emergency on August 14. This initiative was made possible through international collaboration with organizations like the Africa CDC, WHO, Gavi, the Vaccine Alliance, and the Pan American Health Organization.

Pricing and Availability

UNICEF has struck a remarkable deal with a price cap of up to US$65 per vaccine dose, making it the most affordable option available on the market. This agreement guarantees access for countries grappling directly with the outbreak, including the Democratic Republic of the Congo (DRC). As part of the effort, UNICEF is actively exploring additional proposals to secure a robust and diversified supply of mpox vaccines from various manufacturers, ensuring price transparency throughout the process.

Delivery Commitments

Under the terms of this agreement, UNICEF has committed to procure and deliver up to one million doses of the MVA-BN mpox vaccine by the end of 2024. This effort is bolstered with financial support from partners like Gavi, which has pledged backing for 500,000 doses through an Advance Purchase Agreement.

UNICEF's Broader Strategy

Since the onset of the mpox outbreak, UNICEF has been instrumental in assisting the DRC government, facilitating the receipt of over 265,000 doses of mpox vaccines. UNICEF’s comprehensive strategy addresses not just vaccine distribution but aims to halt the virus's transmission, protect children, and bolster community prevention initiatives. Vaccination is one part of a multifaceted approach that includes enhancing infection control, increasing risk communication, and engaging communities actively in the response.

Funding Appeal for Crisis Response

In addition to its vaccination efforts, UNICEF launched a significant appeal for US$58.8 million earlier this month to tackle the mpox crisis in six African countries, where the impact on children is particularly severe. This funding will supplement vaccine donations from wealthier nations, further strengthening the global response to mitigate the health crisis.

Conclusion

As UNICEF continues its vital work in these regions, the world watches closely. Will this pioneering agreement mark a turning point in the fight against mpox? Only time will tell.